Jennifer Broom

Jennifer Broom

Auto-generated profile, based on publicly available information

Jennifer Broom

School of Medicine and Dentistry (Sunshine Coast Campus) Griffith University Sunshine Coast Queensland Australia

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Social Science & Medicine
Verified
Journal Article
Closed access
ABAlex Broom
Alex Broom
JBJennifer Broom
Jennifer Broom
EKEmma Kirby
Emma Kirby

11 February 2020 in Critical Public Health
Verified
Journal Article
Closed access
ABAlex Broom
Alex Broom
KKKatherine Kenny
Katherine Kenny
BPBarbara Prainsack
Barbara Prainsack
JBJennifer Broom
Jennifer Broom
Much has been written about the problem of antimicrobial resistance (AMR) and the action required to rein in this emerging global health threat. Addressing AMR is often operationalised as requiring ‘behavior change’ of clinicians and of patients, in combination with improving the drug development pipeline. Few have approached AMR as a challenge fundamentally embedded within the cultural fabric of modern societies and the (varied) ways they are organised economically, socially and politically. Here, drawing on a decade of work across a range of health contexts, we approach the problem of AMR as one of values and culture rather than of individual behavior. We reframe AMR as a social and political concern resulting from a confluence of factors and practices including: temporal myopia, individualisation, marketisation, and human exceptionalism. To effectively tackle AMR, we advocate solidaristic models that espouse collective responsibility and recognise relative opportunity to act rather than a continuation of the individualistic behavioural models that have, so far, proven largely ineffective.

7 November 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HMHamish McManus
Hamish McManus
COCatherine C O'Connor
Catherine C O'Connor
MBMark Boyd
Mark Boyd
JBJennifer Broom
Jennifer Broom
DRDarren Russell
Darren Russell
ADAustralian Hiv Observational Database
Australian Hiv Observational Database
Life expectancy has increased for newly diagnosed HIV patients since the inception of combination antiretroviral treatment (cART), but there remains a need to better understand the characteristics of long-term survival in HIV-positive patients. We examined long-term survival in HIV-positive patients receiving cART in the Australian HIV Observational Database (AHOD), to describe changes in mortality compared to the general population and to develop longer-term survival models. Data were examined from 2,675 HIV-positive participants in AHOD who started cART. Standardised mortality ratios (SMR) were calculated by age, sex and calendar year across prognostic characteristics using Australian Bureau of Statistics national data as reference. SMRs were examined by years of duration of cART by CD4 and similarly by viral load. Survival was analysed using Cox-proportional hazards and parametric survival models. The overall SMR for all-cause mortality was 3.5 (95% CI: 3.0–4.0). SMRs by CD4 count were 8.6 (95% CI: 7.2–10.2) for CD4<350 cells/µl; 2.1 (95% CI: 1.5–2.9) for CD4 = 350–499 cells/µl; and 1.5 (95% CI: 1.1–2.0) for CD4≥500 cells/µl. SMRs for patients with CD4 counts <350 cells/µL were much higher than for patients with higher CD4 counts across all durations of cART. SMRs for patients with viral loads greater than 400 copies/ml were much higher across all durations of cART. Multivariate models demonstrated improved survival associated with increased recent CD4, reduced recent viral load, younger patients, absence of HBVsAg-positive ever, year of HIV diagnosis and incidence of ADI. Parametric models showed a fairly constant mortality risk by year of cART up to 15 years of treatment. Observed mortality remained fairly constant by duration of cART and was modelled accurately by accepted prognostic factors. These rates did not vary much by duration of treatment. Changes in mortality with age were similar to those in the Australian general population.

27 April 2016 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
JBJennifer Broom
Jennifer Broom
ABAlex Broom
Alex Broom
KAKate Adams
Kate Adams
SPStefanie Plage
Stefanie Plage
Escalating antimicrobial resistance worldwide necessitates urgent optimization of antimicrobial prescribing to preserve antibiotics for future generations. Early intravenous (iv) to oral switch campaigns are one strategy that hospital-based antimicrobial stewardship programmes can incorporate to minimize inappropriate antibiotic use. Yet, iv antibiotics continue to be offered for longer than is clinically indicated, increasing hospital length of stay, increasing costs and placing patients at risk (e.g. cannula-related infections). This study aims to identify why this inappropriate prescribing trend continues. Twenty doctors (9 females and 11 males) working at a teaching hospital in north-east England participated in semi-structured interviews about their experiences of antibiotic use. NVivo10 software was used to conduct a thematic content analysis of the full interview transcripts driven by the framework approach. Results are reported according to COREQ guidelines. Decisions around the choice of iv over oral antibiotics were influenced by three key issues: (i) consumerism, i.e. participants were concerned about the risk of litigation or complaints if patient expectations were not met; (ii) hierarchy of the medical team structure limited opportunities for de-escalation of antibiotics; and (iii) iv antibiotics were perceived as more potent and having significant mythical qualities, which participants acknowledged were not necessarily evidence based. The iv to oral switch interventions should tailor strategies to demystify iv versus oral antibiotic efficacy, engage consumers around the negative effects of iv antibiotic overuse and examine strategies to streamline team decision-making. Addressing these issues has the potential to reduce inappropriate antibiotic use and resistance.

1 August 2016 in Journal of Hospital Infection
Verified
Journal Article
Closed access
JBJ. Broom
J. Broom
ABA. Broom
A. Broom
SPStefanie Plage
Stefanie Plage
KAK. Adams
K. Adams
JPJ.J. Post
J.J. Post

2 November 2012 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
JBJennifer K Broom
Jennifer K Broom
RKRathika Krishnasamy
Rathika Krishnasamy
CHCarmel M Hawley
Carmel M Hawley
EPE Geoffrey Playford
E Geoffrey Playford
DJDavid Johnson
David Johnson
Tunnelled central venous dialysis catheter use is significantly limited by the occurrence of catheter-related infections. This randomised controlled trial assessed the efficacy of a 48 hour 70% ethanol lock vs heparin locks in prolonging the time to the first episode of catheter related blood stream infection (CRBSI).